BioPharma Clinical Trials
Minghui Pharmaceutical Announces Promising Phase I Results for MHB039A, a PD-1 x VEGF Bispecific Antibody, in Solid Tumor Treatment in China
Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today annou...
November 07, 2024 | News
China’s Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment
Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody target...
November 07, 2024 | News
Medidata Introduces Oncology and Vaccine Solutions to Streamline Phase II and III Trials with FDA-Aligned Patient-Centric Design
The new products combine Medidata's diverse technologies and experience from thousands of previous trials to streamline the management of Phase II an...
November 05, 2024 | News
Chipscreen Biosciences Secures NMPA Approval for Phase III Trial of Chiauranib in ES-SCLC Treatment
Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Ph...
November 04, 2024 | News
Hong Kong's Akeso Biopharma Advances Immunotherapy in Biliary Tract Cancer with First Patient Enrolled in Phase III Study of Ivonescimab
Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, c...
November 01, 2024 | News
Hong Kong’s Akeso Biopharma Enrolls First Patient in Pioneering Phase III Trial for Advanced Head and Neck Cancer Therapy
Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (A...
October 31, 2024 | News
Clover Biopharmaceuticals' Non-Adjuvanted RSV Vaccine Candidate SCB-1019 Shows Promising Efficacy and Safety in Head-to-Head Comparison with GSK's AREXVY
- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candi...
October 29, 2024 | News
RiboX Therapeutics Secures FDA IND Clearance for First Circular RNA Therapy, Initiating Clinical Trials for RXRG001
RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, ...
October 28, 2024 | News
LakeShore Biopharma Gains NMPA Approval for Phase III Trial of Simplified Four-Dose Rabies Vaccine Regimen
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developin...
October 28, 2024 | News
MicuRx Achieves Milestone with Successful Phase I Trial of Novel Antibacterial MRX-5 in Australia
Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 in Australi...
October 28, 2024 | News
Corvia Medical’s Atrial Shunt Demonstrates Long-Term Efficacy in Heart Failure Patients: Three-Year Trial Results Published
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced impressive three-year results from its REDUCE LAP-HF II ...
October 28, 2024 | News
South Korea’s Qurient Launches Phase 1 Clinical Trial for Adrixetinib in AML Following FDA IND Clearance
Qurient has announced the commencement of a clinical trial for adrixetinib (formerly named Q702), following the clearance of its investigational new drug (...
October 25, 2024 | News
Pierre Fabre Doses First Patient with PFL-002/VERT-002, a Novel c-MET Degrader for MET-Altered Cancers
PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET, with the potential to be...
October 25, 2024 | News
Taiwan’s Caliway Biopharmaceuticals Completes Final Phase 2b Study of CBL-514, First Injectable for Large-Area Fat Reduction
The first and only lipolytic injectable for large area – CBL-514's last Phase 2b study has been completed Both CBL-514 Phase 2b&nbs...
October 24, 2024 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
